These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8729310)

  • 1. [Prospective evaluation of a nuclear magnetic resonance score in the screening of malignant hyperthermia susceptibility. Initial results].
    Payen JF; Bosson JL; Stieglitz P
    Ann Fr Anesth Reanim; 1996; 15(1):47-48. PubMed ID: 8729310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with 31P-magnetic resonance spectroscopy.
    Payen JF; Bosson JL; Bourdon L; Jacquot C; Le Bas JF; Stieglitz P; Benabid AL
    Anesthesiology; 1993 May; 78(5):848-55. PubMed ID: 8489056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility.
    Olgin J; Rosenberg H; Allen G; Seestedt R; Chance B
    Anesth Analg; 1991 Jan; 72(1):36-47. PubMed ID: 1984374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Definition of a diagnostic score of malignant hyperthermia using P-31 magnetic resonance spectroscopy].
    Bendahan D; Kozak-Ribbens G; Confort-Gouny S; Cozzone PJ
    Ann Fr Anesth Reanim; 1996; 15(5):583-8. PubMed ID: 9033751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive evaluation of malignant hyperthermia susceptibility with phosphorus nuclear magnetic resonance spectroscopy.
    Olgin J; Argov Z; Rosenberg H; Tuchler M; Chance B
    Anesthesiology; 1988 Apr; 68(4):507-13. PubMed ID: 3354887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 31Phosphorus magnetic resonance spectroscopy characterization of muscular metabolic anomalies in patients with malignant hyperthermia: application to diagnosis.
    Bendahan D; Kozak-Ribbens G; Rodet L; Confort-Gouny S; Cozzone PJ
    Anesthesiology; 1998 Jan; 88(1):96-107. PubMed ID: 9447862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An analysis of the predictive probability of the in vitro contracture test for determining susceptibility to malignant hyperthermia.
    Hopkins PM; Ellis FR; Halsall PJ; Stewart AD
    Anesth Analg; 1997 Mar; 84(3):648-56. PubMed ID: 9052318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
    Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
    Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ryanodine contracture threshold times for diagnosis of malignant hyperthermia susceptibility: an experimental approach from a single laboratory.
    Weisshorn R; Wappler F; Fiege M; Gerbershagen MU; Kolodzie K; Alberts P; Horn EP; Schulte Am Esch J
    J Clin Anesth; 2004 Aug; 16(5):353-7. PubMed ID: 15374556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical concentrations of verapamil affect the in vitro diagnosis of susceptibility to malignant hyperpyrexia.
    Adnet PJ; Krivosic-Horber RM; Adamantidis MM; Haudecoeur G; Reyfort GH; Dupuis BA
    Br J Anaesth; 1990 Jan; 64(1):64-6. PubMed ID: 2302378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
    Mortier W; Breucking E
    Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
    Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
    Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnosis of susceptibility to malignant hyperthermia using the in vitro contracture test].
    Klein W; Spiess-Kiefer C; Küther G; Pongratz D; Lehmann-Horn F
    Anaesthesist; 1987 Dec; 36(12):685-91. PubMed ID: 2830805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sevoflurane is less sensitive than halothane for in vitro detection of malignant hyperthermia susceptibility.
    Johannsen S; Klingler W; Schneiderbanger D; Heiderich S; Roewer N; Schuster F
    Acta Anaesthesiol Scand; 2013 Oct; 57(9):1161-6. PubMed ID: 23957432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of in vitro contracture testing of both parents of malignant hyperthermia susceptible probands.
    Islander G; Bendixen D; Ranklev-Twetman E; Ording H
    Acta Anaesthesiol Scand; 1996 May; 40(5):579-84. PubMed ID: 8792888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of peranesthetic malignant hyperthermia by muscle contracture tests and NMR spectroscopy].
    Kozak-Reiss G; Gascard JP; Redouane-Bénichou K
    Ann Fr Anesth Reanim; 1986; 5(6):584-9. PubMed ID: 3826791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia.
    Hopkins PM; Ellis FR; Halsall PJ
    Br J Anaesth; 1991 May; 66(5):611-3. PubMed ID: 2031823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia.
    Sato N; Brum JM; Mitsumoto H; DeBoer GE
    Can J Anaesth; 1995 Feb; 42(2):158-62. PubMed ID: 7720160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro 31P-magnetic resonance spectroscopy of muscle extracts in malignant hyperthermia-susceptible patients.
    Payen JF; Fouilhé N; Sam-Lai E; Rémy C; Dupeyre R; Mézin P; Halsall J; Stieglitz P
    Anesthesiology; 1996 May; 84(5):1077-82. PubMed ID: 8624001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
    Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
    Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.